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ABSTRACT
Background: Hemoptysis is an alarming and common symptom leading to thorough diagnostic
evaluation with computed tomography and fiberoptic bronchoscopy. Increasing evidence sug-
gests that bronchoscopy is not necessary in diagnosing lung cancer in hemoptysis patients
because of high sensitivity of computed tomography. However, less attention has been paid to
non-malignant etiologies of hemoptysis.
Objective: We aimed to identify the etiologies established in hemoptysis patients with no
malignancy suspected on computed tomography in order to assess the necessity of broncho-
scopy in these patients.
Design: We retrospectively reviewed clinical records of consecutive patients referred to evalua-
tion for hemoptysis with no malignancy suspected on computed tomography at Aalborg
University Hospital, Denmark, in an eleven-year period from 2006 to 2016.
Results: One thousand one hundred and eighty-five patients (mean age 57.5 ± 15.44 years, 61.3%
male) were included in the study. Bronchoscopy was performed in 91.9% of cases. Most patients
(83.5%) had cryptogenic hemoptysis, while the most frequently identified etiologies were respira-
tory tract infection (12.6%) and bronchiectasis (2.2%). No patients had malignant disease as their
etiology.
Conclusions: The vast majority of hemoptysis cases with no malignancy suspected on computed
tomography were cryptogenic and all were benign. Bronchoscopy may be reserved for patients
with specific conditions suspected and those with persistent symptomatology.
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Introduction
Hemoptysis, defined as the coughing or spitting of blood
from the lower airways, is an alarming symptom for the
patient and has a wide variety of etiologies ranging from
benign conditions to malignancies of the tracheobron-
chial tree and lung parenchyma [1–3].
In previous literature, the etiologies of hemoptysis vary
greatly. Lung cancer prevalences between 4 and 30% have
been reported in hemoptysis patients in later years [4–
13], the lowest of these in Danish populations.
Bronchiectasis has been reported as the etiology of
hemoptysis in 6–33% of cases [4–12] and pneumonia in
4–16% [4,6–9,12,14]. Cryptogenic hemoptysis, in which
diagnostic evaluation with thoracic imaging and fiberop-
tic bronchoscopy does not result in a diagnosis, has been
reported as the etiology of hemoptysis in 5–50% of cases
[4,6–13]. Other common etiologies include tuberculosis,
fungal infections, and pulmonary embolisms [1].
Current guidelines from the Danish Society of
Respiratory Medicine for the diagnostic evaluation of
hemoptysis include computed tomography (CT) in all
patients aged ≥40 years, smokers, or experiencing symp-
toms suspicious of malignancy. Bronchoscopy is recom-
mended with continuous suspicion of malignancy, severe
or persistent hemoptysis or abnormal CT [15]. The lit-
erature agrees on the use of chest x-ray, CT, and broncho-
scopy in the evaluation of hemoptysis, but no
international scientific consensus seems to have been
reached with regard to the priority and distribution of
those investigations [4]. Increasing evidence suggests that
bronchoscopy is not necessary in hemoptysis patients
with no pathology on CT [4,11]. However, these reports
primarily focus on the ability to diagnose cancer correctly
and less attention has been paid to the majority of etiol-
ogies comprising non-malignant diagnoses. In daily prac-
tice, a large number of bronchoscopies are performed
which is unpleasant and not without risk for the patient
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while expensive and time-consuming procedures for the
health-care system. To our knowledge, no larger studies
have addressed the necessity of bronchoscopy in patients
not suspected of malignancy.
We hypothesize that the etiologies identified in
hemoptysis patients with no malignancy suspected on
chest CT are indeed non-malignant etiologies. Hence,
we aim to evaluate the frequencies of different etiolo-
gies in this patient group. What are the etiologies
established in hemoptysis patients with no suspicion
of malignancy on CT, and how does fiberoptic
bronchoscopy contribute to the diagnosis? Also, we
aim to compare the rate of non-cryptogenic hemopty-
sis between patients with no pathology on CT and
those with any non-malignant pathology on CT and
identify possible risk factors for the various etiologies.
Materials and methods
Setup and study population
This retrospective study reviewed clinical records of
patients referred to the Department of Respiratory
Diseases, Aalborg University Hospital, Denmark for eva-
luation of hemoptysis, identified by the ICD-10 diagnosis
DR042 from January 1,, 2006, to December 31, 2016.
Exclusion criteria were: under 18 years of age; previous
evaluation for hemoptysis; evaluation cancelled for any
reason; bleeding not originating from the lower airways
as assessed on first visit; no chest CT or no CT descrip-
tion; and CT suspicious of pulmonary malignancy.
Part of the population studied here are also pre-
sented in another study from our group [16].
Data collection and definitions
From the patient record, the following parameters were
recorded: gender; age; present somatic diseases at refer-
ral; previous somatic diseases (diagnoses no longer
applicable to the patient at referral); amount of hemop-
tysis (mild (<30 ml/24 h); moderate-massive (≥30 ml/
24 h)) [10]; episodes of hemoptysis (1–5, >5); antic-
oagulant treatment at referral; and smoking history
(never, ex-smoker (>6 months absence), smoker).
If not noted independently, present somatic diseases
were estimated from the medication listed in the
patient record. Anticoagulant treatment was grouped
as thrombocyte-inhibitors, novel oral anticoagulants
(NOACs), coumarins, and anti-thrombin activators.
Smoking history in smokers and ex-smokers was quan-
tified in pack-years (≤30, >30) [17].
Results of chest CT were obtained from the radiolo-
gical description of the scan. Scans older than 2 months
at referral were not considered. Any abnormality of the
lungs, except for emphysematic shape of the thorax and
normal anatomical variations, was considered a positive
investigation. Lesions were grouped as bronchiectasis,
pneumonia, interstitial disease, suspicion of fungal infec-
tion, pulmonary embolism, fibrotic tissue and ‘other’. If
a scan was described with more than one lesion, all were
recorded.
Bronchoscopy was assessed by the description from
the investigating physician and considered macrosco-
pically positive if it identified: the site of bleeding;
a tumor or foreign body; a substantially vulnerable
mucosa; or sequelae after previous surgery.
Results of histological, cytological, and microbiolo-
gical samples were obtained from the respective inte-
grated result application of the patient record.
Histology and cytology were considered positive if
suggestive of dysplasia or malignancy. Metaplasia and
inflammation were not considered positive unless the
pattern of inflammation suggested interstitial lung dis-
ease. As to microbiology, any growth not described as
normal flora was considered positive, as was positive
polymerase chain reaction (PCR) for mycobacteria.
Etiologies were defined as the diagnoses stated or
acted upon by the physician at the end of initial diag-
nostic workup, regardless of the findings of the diag-
nostic modalities. Etiologies were grouped into primary
lung cancers, metastatic cancer to the lungs, bronch-
iectasis, mycobacterial infections, fungal infections,
respiratory tract infection (including all but mycobac-
terial and fungal infections) and interstitial lung dis-
ease. Other etiologies were recorded individually. In
patients with more than one final diagnosis, all were
recorded as etiologies. Cases with no established etiol-
ogy were recorded as cryptogenic, while all other etiol-
ogies were grouped as non-cryptogenic etiologies for
subanalyses.
Data management, statistics, and approvals
Study data were collected and managed using REDCap
electronic data capture tools hosted at Aalborg University
Hospital [18].
Descriptive statistics were carried out using the inte-
grated ‘Data Exports, Reports, and Stats’ module of
REDCap and IBM SPSS Statistics for Macintosh,
Version 25.0. The latter was also used for hypothesis
testing, cross tabulations and computing of risk ratios.
Normally distributed data was presented as mean and
standard deviation (SD), while frequencies were pre-
sented as absolute numbers and percentages of cases
with relevant data available. Cross tabulations and chi-
square tests were applied to compare categorical
2 C. L. PETERSEN AND U. M. WEINREICH
variables between groups and independent t-test to
compare age means between groups. Risk ratios were
presented along with confidence intervals. A significance
level of 95% applied to all tests.
The study was approved by the Danish Patient
Safety Authority with case ID 3-3013-2350/1/and by
the Danish Data Protection Agency under the umbrella
application for the North Denmark Region (2008-58-
0028) with project ID 2017–60.
Results
Study population and baseline characteristics
A total of 1493 patients were referred with hemoptysis
during the study period. Of these, 308 met one or more
exclusion criteria, leaving 1185 patients to be included
in the study. The inclusion process is depicted in
Figure 1.
Baseline characteristics are shown in Table 1.
Present and previous health data are presented in
Figure 2. No present somatic disease was known at the
time of referral in 42.7% of patients, and 51.1% of
patients had no previous somatic diseases. As shown
in Figure 2, COPD was known in 12.9% of patients
while 1.5% had bronchiectasis and 2.1% were pre-
viously treated for lung cancer.
Results of diagnostic modalities
All 1185 patients had chest CT performed and CT was
positive in 71.3% of cases, the most frequent findings
being fibrotic tissue (25.8%), bronchiectasis (18.2%)
and ‘other’ (56.7%). Bronchoscopy was performed in
91.9% of patients. Microbiological sampling was per-
formed in 59.9% of patients, and 24.4% of these were
positive. Proportions of positive findings from the
diagnostic modalities are shown in Table 2 along with
the proportions of CT lesions.
Etiologies and risk factors
Cryptogenic hemoptysis was the final diagnosis in 989
(83.5%) patients. No patients were diagnosed with pri-
mary or secondary cancer in the lungs. The most
frequent etiology was respiratory tract infection
(12.6%), constituting 76% of non-cryptogenic cases,
followed by bronchiectasis (2.2%). Seven patients had
a double diagnosis of bronchiectasis and respiratory
tract infection. Respiratory tract infection was the
recorded etiology in 20% of patients with bronchiecta-
sis on CT, while bronchiectasis was the recorded etiol-
ogy in 11% of patients with bronchiectasis on CT. All
etiologies are shown in Figure 3.
In patients with a negative CT an etiology was
identified in 28 patients (8%). The etiologies were
respiratory tract infection (89.3%), asthma (7.1%) and
hemangioma (3.6%).
An etiology was obtained significantly more fre-
quently in patients with a positive CT than in patients
Figure 1. Inclusion process and excluded patients by exclusion
criterium.
Table 1. Baseline characteristics. Absolute numbers (%), where
not stated otherwise. Percentages of patients with relevant
data available (n).
Mean age, years (SD) (n = 1,185) 57.5 (14.55)
Male (n = 1,185) 726 (61.3)
Smoking (n = 1,164) 871 (74.8)
Current (n = 1,164) 476 (40.9)
Previous (n = 1,164) 395 (33.9)
Pack years >30 (n = 1,125) 290 (25.8)
Anticoagulant treatment (n = 1,150) 335 (29.1)
Thrombocyte inhibitors (n = 334) 246 (73.7)
Coumarins (n = 334) 87 (26.0)
NOACs1 (n = 334) 25 (7.5)
Antithrombin activators (n = 334) 6 (1.8)
Amount of hemoptysis (n = 761)
Mild 663 (87.1)
Moderate – massive 98 (12.9)
Episodes (n = 1,036)
1–5 565 (54.5)
>5 471 (45.5)
Current/prev. lung disease (n = 1,168) 291 (24.9)
1: Novel oral anticoagulants
EUROPEAN CLINICAL RESPIRATORY JOURNAL 3
with a normal CT (19.9% vs. 8.2%, p < 0.001 – RR
2.414, CI 1.651–3.529) as were the two most frequent
etiologies, respiratory tract infection (14.7% vs. 7.4%,
p = 0.001 – RR 1.996, CI 1.323–3.010) and bronchiec-
tasis (3.1% vs. 0%, p = 0.001).
Of patients with respiratory tract infection as their
etiology, 144 (96.6%) had microbiological sampling
performed, and 141 (98%) of these were positive.
Patients with non-cryptogenic hemoptysis were signif-
icantly older than those with cryptogenic hemoptysis
(59.81 vs. 57.01 years, p = 0.014). Patients aged over 60
had significantly higher rates of non-cryptogenic hemop-
tysis (19.0% vs. 14.5%, p = 0.036 – RR 1.314, CI 1.017–
1.697). Patients with current or previous lung disease also
had higher rates of identified etiologies (24.7% vs. 13.9%,
p < 0.001 – RR 1.784, CI 1.377–2.310) and higher rates of
respiratory tract infections (21.6% vs. 9.6%, p < 0.001 –
RR 2.251, CI 1.672–3.028). No significant correlations
were found with other final diagnoses in either group,
neither were any significant associations found between
final diagnoses and gender, pack-years >30, number of
events of hemoptysis or volume of hemoptysis. Use of
vitamin K antagonists was associated with higher rates
of identified etiologies (25.3% vs. 15.8%, p = 0.023 – RR
1.596, CI 1.085–2.348), but no associations were found
for other types of anticoagulants.
Discussion
This study supports the initial hypothesis that hemop-
tysis patients with no malignancy suspected on CT are
diagnosed with non-malignant conditions. No malig-
nant diagnoses were established in the study population.
The initial diagnostic workup resulted in cryptogenic
hemoptysis in 83.5% of patients, and the most prevalent
non-cryptogenic etiologies were respiratory tract infec-
tion (12.6%) and bronchiectasis (2.2%).
Etiologic distribution in hemoptysis patients
In this study, the proportion of cryptogenic hemoptysis
is 83.5% which is considerably higher than those
reported in similar studies: Nielsen et al. reported
52.5% to be cryptogenic in a comparable Danish popu-
lation [4], while studies from the UK, Ireland, and
France reported 5.8%, 18%, and 50%, respectively, in
populations also similar to ours with regard to gender
distribution, age, and smoking history [7,11,13]. In the
Danish study, a consensus diagnosis would be agreed
on retrospectively if no etiology was established at
initial workup, which may explain the lower propor-
tion of undiagnosed patients in this study. Similarly,
the low proportion in the Irish study may be due to an
Table 2. Number of investigations performed and percentage
of all patients, along with number of positive investigations
and percentage of the number performed.
Performed (%) Positive (%)
Computed tomography 1,185 (100) 845 (71.3)
Fibrotic tissue 306 (25.8)
Bronchiectasis 216 (18.2)
Respiratory tract infection 70 (5.9)
Interstitial lung disease 9 (0.8)
Fungal infection 4 (0.3)
Pulmonary embolism 2 (0.2)
Other 672 (56.7)
Bronchoscopy or test 1,089 (91.9) 445 (40.9)
Bronchoscopy 1,089 (91.9) 353 (32.4)
Microbiology 710 (59.9) 173 (24.4)
Cytology 580 (48.9) 5 (0.9)
Histology 62 (5.2) 4 (6.5)
42,7%
51,1%
12,9%
0,0%
7,7%
1,1%
1,5%
0,0%0,9% 0,7%0,3%
1,4%
0,1% 0,1%0,0%
2,1%1,8%
8,2%
65,3%
42,8%
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
70,0%
Present (n=1,170) Previous (n=1,157)
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Figure 2. Patients with somatic diagnoses applicable at referral (present) and no longer applicable at referral (previous), as
percentage of patients with relevant data available (n).
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included follow-up of at least 6 months, while the
French study is limited by being based on diagnostic
coding alone, and the UK study found high propor-
tions of acute and chronic bronchitis, an etiology not
reported in our study. Much lower proportions of
cryptogenic hemoptysis are found in reports from
other countries, in which lung cancer and tuberculosis
make up substantially larger proportions of hemoptysis
cases [8,10,12]. As such, we believe the high frequency
of cryptogenic hemoptysis in our study to be explained
by differences in study designs and low prevalences of
other etiologies such as tuberculosis.
The two most frequent non-cryptogenic etiologies for
hemoptysis in this study, respiratory tract infection
(12.6%) and bronchiectasis (2.2%), are consistently
reported as major etiologies in previous studies.
However, for both of these, considerable variations in
reported frequencies exist due to differences in defini-
tions and reporting methods. Most other studies have
reported in terms of pneumonia rather than respiratory
tract infection, the definition of which varying markedly
between reports. Nielsen et al. reported pneumonia as the
etiology in 34% of non-cryptogenic cases [4] and the
corresponding proportion was approx. 46% in the
French population [13], whereas Thirumaran et al.
reported only 10%, in part because acute bronchitis con-
stituted 67% of diagnoses [7]. Similar variations can also
be found and correspondingly explained for bronchiec-
tasis [4,5,7,9,10,19]. In our study, radiological findings of
bronchiectasis were considerably more prevalent than the
final diagnosis of bronchiectasis. Also, 20% of patients
with a radiological finding of bronchiectasis had respira-
tory tract infection recorded as their etiology while
bronchiectasis was the recorded etiology in just 11% of
patients with bronchiectasis on CT. Thus, a considerable
proportion of the respiratory tract infections identified
may be associated with underlying bronchiectasis, sug-
gesting an underestimation of the proportion of bronch-
iectasis as the cause of hemoptysis. Nonetheless, it is
widely agreed that respiratory tract infection and bronch-
iectasis, diagnoses not consistently requiring broncho-
scopy, are leading causes of hemoptysis.
The only etiologies identified in our study strictly
requiring bronchoscopy and bronchoscopic sampling
are the two hemangiomas, the one leiomyoma, and the
seven cases of interstitial lung diseases, which are seen
in only 0.8% of patients. Mycobacterial and fungal
infections may be suspected from sputum prior to
performing bronchoscopy, although most cases do
require bronchoscopy to confirm the diagnosis before
initiation of treatment.
With a considerably higher number of study sub-
jects than most previous studies, our data suggest that
only very few patients with no malignancy suspected
on CT will benefit more from bronchoscopy than from
non-invasive investigations. This is consistent with pre-
vious reports of slightly different perspectives [4,5,11].
Thus, we argue that bronchoscopy is reserved for
patients with specific conditions suspected or with
persistent symptomatology. We recommend that
bronchoscopy should be performed only after careful
consideration of the necessity of invasive investigation
989 (83.5 %)
149 (12.6 %)
26 (2.2 %)
7 (0.6 %)
5 (0.4 %)
4 (0.3 %)
2 (0.2 %)
2 (0.2 %)
2 (0.2 %)
2 (0.2 %)
1 (0.1 %)
1 (0.1 %)
1 (0.1 %)
1 (0.1 %)
0 (0 %)
00010080060040020
Cryptogenic
Bronchiectasis
Interstitial lung disease
Asthma
Pulmonaryembolism
Fungal infection
COPD
Hemangioma
Wegener'sgranulomatosis
Mycobacteria
Leiomyoma
Pneumothorax
Intrathoracic goiter
Malignancy
Respiratory tract infection
Figure 3. Etiologies of hemoptysis. Absolute numbers (percentages).
EUROPEAN CLINICAL RESPIRATORY JOURNAL 5
rather than as a routine investigation in hemoptysis
patients with no malignancy suspected on CT.
Since the predominant etiology is respiratory tract
infection, sputum culture may be a relevant second-line
investigation in patients with no etiology evident from
CT. Since microbiological evaluation was only per-
formed in 60% of patients, and since one-fourth of
these samples turned out positive, sputum culture
may even be considered before CT in order to optimize
the detection of respiratory tract infections. Ideally at
the first contact with the medical system, which in our
case would be to primary care.
Risk factors for non-cryptogenic hemoptysis
The only identified risk factors for non-cryptogenic
hemoptysis in our study were age >60, previous or
current lung disease and a positive CT scan. Risk
factors for respiratory tract infection were previous or
current lung disease and a positive CT scan. The latter
was also a risk factor for bronchiectasis. Smoking his-
tory was not found to be an independent risk factor for
any etiology. The literature only considers age and
smoking history in relation to hemoptysis caused by
cancer and is therefore not comparable to this study.
Few studies have assessed risk factors for etiologies
other than lung cancer in hemoptysis patients.
Bronchiectasis has been reported to be associated
with female gender [9] and moderate to severe hemop-
tysis [19], while pulmonary embolism has been found
associated with mild to moderate hemoptysis [12].
Others, however, found no associations between the
amount of hemoptysis and etiology [6] or between
gender or race and etiology [20]. No such correlations
were found in the present study.
Strengths and limitations
The retrospective design of the study has multiple
built-in limitations especially regarding missing data
from the clinical records. Also, some results are based
on interpretations of clinical reports and procedure
descriptions that did not explicitly state the outcome
we were looking for. However, a strict methodology
and well-defined variables along with the large sample
provide a solid foundation for analyses.
In a prospective design with all patients investigated
by all diagnostic modalities, it is possible that more
etiologies would be identified. However, with the very
low proportion of non-cryptogenic hemoptysis in our
study and the high proportion of investigations per-
formed, we do not believe that this would markedly
alter the overall interpretation of the study.
With the present design, we cannot know whether
or not some conditions were overlooked by the diag-
nostic workup. This may be addressed by a study on
the same patient population to identify new diagnoses
within a follow-up period, as was done by
Tsoumakidou et al. who found no new cases of lung
cancer in a 2.7-year follow-up [9].
With regard to the inclusion of patients, 59 of the
identified patients were excluded because they declined
evaluation or did not show up while one patient died
before evaluation. This may have been due to poor
health, which might have influenced the rate of serious
diagnoses in our population. Conversely, 82 patients
were excluded because they did not have CT per-
formed, which may be due to very little suspicion of
serious disease. All things considered, we believe selec-
tion bias to be minimal in our study.
Conclusion
The majority of hemoptysis patients with no malig-
nancy suspected on CT had cryptogenic hemoptysis
and all etiologies identified were benign, generally not
requiring bronchoscopy. Bronchoscopy may be
reserved for patients with specific conditions suspected
or persistent symptomatology. Sputum culture may be
an alternative second-line investigation, while
bronchoscopy should be performed only after careful
consideration of the necessity of invasive investigation.
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